Top Compounds Detected Within Samples Collected in June 2024
Total number of samples tested: 868
1. Methamphetamine (38%)
2. Fentanyl (35%)
3. 4-ANPP (17%)
4. Xylazine (14%)
5. Acetaminophen (12%)
6. Cocaine (9%)
7. Heroin (8%)
8. 6-Monoacetylmorphine (8%)
9. Quinine (5%)
10. Papaverine (5%)
Top Compounds Detected Within Samples Collected in June 2024 (West Coast and East Coast)
|
West Coast (n=578)
|
East Coast (n=263)
|
|
1. Methamphetamine (65%)
|
1. Fentanyl (59%)
|
|
2. Fentanyl (27%)
|
2. Xylazine (38%)
|
|
3. 4-ANPP (16%)
|
3. Methamphetamine (22%)
|
|
4. Acetaminophen (15%)
|
4. Cocaine (21%)
|
|
5. Heroin (12%)
|
5. 4-ANPP (20%)
|
|
6. 6-Monoacetylmorphine (11%)
|
6. Quinine (16%)
|
|
7. Papaverine (7%)
|
7. Medetomidine (9%)
|
|
8. 6-Acetylcodeine (7%)
|
8. Tetracaine (8%)
|
|
9. Noscapine (6%)
|
9. Caffeine (8%)
|
|
10. N,N-Dimethylamphetamine (4%)
|
10. Acetaminophen (7%)
|
Numbers in parentheses are percentages of samples containing the listed compound, excluding samples where no compounds were detected.
Samples analyzed and included in this count are voluntary samples collected and provided by public health and harm reduction agencies from across the country. The trends observed in these samples may not be representative of broader trends within the United States drug supply. All testing was qualitative in nature. Testing of salt form or determination of salt versus free base was not completed.
Recent Trends and New Compounds
Below are several graphs depicting trends from samples received over the past three or six months. In the top graph, drug class and select individual compound prevalence are presented. For June 2024, the total results (grey bar) are also broken out into West coast (yellow bar) and East coast (pink bar). Note that in many instances there are multiple compounds identified in a single sample. Counts and percentages are preliminary and based on samples received by the date this newsletter is released. Data from prior months has been updated with results from any additional samples received.
The center left graph presents co-detection of fentanyl and xylazine. Of the samples collected in June 2024 where fentanyl and/or xylazine were detected, both compounds were found in 32% of samples. Xylazine without fentanyl was detected in 5% of samples. Fentanyl without xylazine was detected in 63% of samples. The number of samples where fentanyl was detected without xylazine was higher than the previous month. Differences between West cost and East coast samples are shown on the right side of the graph.
The center right graph shows co-detection of fentanyl with amphetamines, benzodiazepines, cocaine, and nitazenes over the last three months. For June 2024, the total results (grey bar) are also broken out into West coast (yellow bar) and East coast (pink bar). Note that many of the samples tested are used syringes where co-use of compounds cannot be ruled out, possibly inflating these values.
The bottom graph is a breakdown of the types of paraphernalia that were sampled and analyzed in June 2024, when reported. Used syringes accounted for approximately 51% of all samples and 57% of samples where the paraphernalia type was known.
 In June 2024, one compound was detected for the first time in RaDAR samples. Note that compounds discussed here are those that have been newly detected in RaDAR samples. This does not mean that it is the first identification of the compound in the illicit drug supply.
Etomidate, a sedative, was detected in a single East Coast sample that also contained fentanyl and tetracaine. The enantiomer (R- or S-) of etomidate was not determined. |
|
 |
 |
|
There is continued prevalence of medetomidine in East Coast samples also containing fentanyl. Medetomidine was found in more than 30% of fentanyl samples in multiple East Coast states in June. Multiple samples containing medetomidine and tetracaine, without fentanyl, were also identified. |
RaDAR in the News
We Need Comprehensive Illicit Drug Analysis Now to Stop Overdose Deaths
"The devastating, drug overdose epidemic in the U.S. killed over 105,000 people last year, most from the synthetic opioid fentanyl. But while fentanyl has dominated the headlines, talk in public health circles has shifted to a new illicit drug on the street: xylazine..." Read More.
Recent Publications
Beyond Fentanyl Test Strips: Investigating Other Urine Drug Test Strips for Drug Checking Applications
Use of immunoassay test strips for the detection of fentanyl in drug samples has become increasingly commonplace in harm reduction, law enforcement, public health, customs, and forensic science settings. With the increase of xylazine in the drug supply in recent years, use of xylazine test strips has also begun to take root. As adoption and implementation of this tool continues, a desire to implement test strips for other drugs may emerge. However, since these strips are designed for urine testing, it is important to understand their applicability to testing drugs themselves. Read More.
An Analytical Platform for Near Real-Time Drug Landscape Monitoring Using Paraphernalia Residues
Deaths attributed to drug overdoses are constantly on the rise, but drug trends are frequently changing and often differ across geographical regions. Current analytical techniques are limited in their abilities to rapidly identify drugs that would inform both public health and law enforcement officials about the evolving drug landscape. Read More.
|
